Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15

Breast Cancer Research

Volumn 15, Issue 3, 2013, Pages

  Lehmann Che, Jacqueline ^a,b,c   Hamy, Anne Sophie ^a   Porcher, Raphaël ^a   Barritault, Marc ^a,b   Bouhidel, Fatiha ^a   Habuellelah, Hanadi ^a   Leman Detours, Solenne ^a   de Roquancourt, Anne ^a   Cahen Doidy, Laurence ^a   Bourstyn, Edwige ^a   de Cremoux, Patricia ^a,b,c   de Bazelaire, Cedric ^a   Albiter, Marcela ^a   Giacchetti, Sylvie ^a   Cuvier, Caroline ^a   Janin, Anne ^a,d   Espié, Marc ^a   de Thé, Hugues ^a,b,c   Bertheau, Philippe ^a,c,d  

^a SAINT LOUIS HOSPITAL   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSERM   (France)

Author keywords

basal like; breast carcinoma; cancer; estrogen receptor; GCDFP15; HER2; molecular apocrine; triple negative

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; CARRIER PROTEIN; ERBB2 PROTEIN, HUMAN; GLYCOPROTEIN; PIP PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR APOCRINE BREAST CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; APOCRINE GLAND; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOCRINE GLANDS; BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84877272007     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3421     Document Type: Article

References (41)

1. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998, 3:95-103. 10.1023/A:1018730519839, 10819508.
2. Park S, Koo J, Park HS, Kim J-H, Choi S-Y, Lee JH, Park B-W, Lee KS. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010, 21:488-492. 10.1093/annonc/mdp510, 19887463.
3. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz A-L, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671. 10.1038/sj.onc.1208561, 15897907.
4. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008. 10.1038/sj.onc.1209415, 16491124.
5. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C. A refined molecular taxonomy of breast cancer. Oncogene 2012, 31:1196-1206. 10.1038/onc.2011.301, 3307061, 21785460.
6. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003, 98:703-711. 10.1002/cncr.11532, 12910513.
7. Marisa L, de Reynies A, Guedj M. citbcmst: Assigning tumor samples to CIT Breast Cancer Molecular Subtypes from gene expression data. , http://cran.r-project.org/web/packages/citbcmst/index.html
8. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. Evaluation of androgen, estrogen (ERα and ERβ), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001, 61:1919-1926.
9. Budczies J, Klauschen F, Sinn BV, Gyo{double acute}rffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 2012, 7:e51862. 10.1371/journal.pone.0051862, 3522617, 23251644.
10. Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, de Roquancourt A, Plassa L-F, Giacchetti S, Espié M, de Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, de Thé H, Bertheau P. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br J Cancer 2011, 104:1739-1746. 10.1038/bjc.2011.135, 3111154, 21540864.
11. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995, 92:3963-3967. 10.1073/pnas.92.9.3963, 42082, 7732013.
12. Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P, Frebourg T, Iggo R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997, 14:163-169. 10.1038/sj.onc.1200812, 9010218.
13. Varna M, Lehmann-Che J, Turpin E, Marangoni E, El Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa L-F, Ferreira I, Poupon M-F, Janin A, de Thé H, Bertheau P. p53 dependent cell cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 2009, 124:991-997. 10.1002/ijc.24049, 19048622.
14. Santarpia M, Altavilla G, Margeli M, Cirauqui B, Mesiti M, Cavallari V, Ramirez JL, Sanchez-Ronco M, Santarpia L, Taron M, Rosell R. PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance. Cancer Invest 2008, 26:1044-1051. 10.1080/07357900802112701, 18798071.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43. American Society of Clinical Oncology/College of American Pathologists.
16. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008, 21(Suppl 2):S8-S15.
17. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees 1984, London: Chapman and Hall.
18. Shih Y-S. Selecting the best splits for classification trees with categorical variables. Stat Probabil Lett 2001, 54:341-345.
19. R Development Core Team R: A Language and Environment for Statistical Computing 2009, Vienna, Austria: R Foundation for Statistical Computing, R Development Core Team.
20. Ripley B. Tree: Classifcation and Regression Trees 2010. R package version 1.0-28 , http://CRAN.R-project.org/package=tree
21. O'Malley FP, Page DL, Nelson EH, Dupont WD. Ductal carcinoma in situ of the breast with apocrine cytology: definition of a borderline category. Hum Pathol 1994, 25:164-168. 10.1016/0046-8177(94)90273-9, 8119716.
22. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod Pathol 1994, 7:813-818.
23. Tavassoli FA, Devilee P, World Health Organization Tumours of the Breast and Female Genital Organs - Pathology and Genetics 2003, Lyon, France: IARC Press, World Health Organization.
24. Zagorianakou P, Zagorianakou N, Stefanou D, Makrydimas G, Agnantis NJ. The enigmatic nature of apocrine breast lesions. Virchows Arch 2006, 448:525-531. 10.1007/s00428-005-0095-z, 16570182.
25. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008, 216:141-150. 10.1002/path.2407, 18720457.
26. Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F. Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol Oncol 2009, 3:220-237. 10.1016/j.molonc.2009.01.005, 19393583.
27. Vranic S, Gatalica Z, Deng H, Frkovic-Grazio S, Lee LM, Gurjeva O, Wang ZY. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol 2011, 64:54-57. 10.1136/jcp.2010.082776, 3380072, 21045236.
28. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010, 23:205-212. 10.1038/modpathol.2009.159, 19898421.
29. Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 2009, 11:R40. 10.1186/bcr2327, 2716509, 19549328.
30. Baniwal SK, Little GH, Chimge N-O, Frenkel B. Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 2012, 227:2276-2282. 10.1002/jcp.22966, 3376385, 21809344.
31. Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, Kiang DT. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 1989, 20:281-287. 10.1016/0046-8177(89)90137-8, 2542151.
32. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009, 15:2472-2478. 10.1158/1078-0432.CCR-08-1763, 19276248.
33. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007, 9:1152-1159. 10.1593/neo.07769, 2134911, 18084622.
34. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011, 24:924-931. 10.1038/modpathol.2011.54, 3128675, 21552212.
35. Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011, 130:477-487. 10.1007/s10549-011-1715-8, 21837479.
36. Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, Rodriguez JC, Lamelas ML, Vizoso FJ. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008, 8:149. 10.1186/1471-2407-8-149, 2416360, 18507821.
37. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA, Tamimi RM. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011, 17:1867-1874. 10.1158/1078-0432.CCR-10-2021, 3076683, 21325075.
38. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003, 120:725-731. 10.1309/42F00D0DJD0J5EDT, 14608899.
39. Luo X, Shi Y-X, Li Z-M, Jiang W-Q. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 2010, 29:585-590. 10.5732/cjc.009.10673, 20507730.
40. Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010, 12:R63. 10.1186/bcr2626, 2949656, 20712882.
41. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767. 10.1172/JCI45014, 3127435, 21633166.